Liberate Program News Today

LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Ph

September 11, 2023

-- Industry veteran brings more than 30 years of operational experience, in large pharma and emerging stage biotech, private and public companies, with extensive commercial experience and an established track record of financing in the capital markets-- Lerodalcibep, a novel, next generation PCSK9 inhibitor and the...

University Of Cincinnati United States Evan Stein August Troendle David Cory Smith Kline

Source: pharmiweb.com

Navigation

Liberate Program News Today

LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China

LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Ph

Explore More Categories